Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Monday, November 14, 2022, inter alia, to approve and take on record the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2022, amongst other routine matters. The Company will organize an Earnings Conference Call for analysts/investors on Tuesday, November 15, 2022. The details of the same will be available on the Company's website closer to the scheduled event.
20-10-2022
Bigul

BIOCON LTD. - 532523 - Closure of Trading Window

 The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading ('the Code') of the Company, has been closed from October 1, 2022 to November 16, 2022 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations.
20-10-2022
Bigul

BIOCON LTD. - 532523 - Board Meeting Intimation for Board Meeting Intimation For Approval Of Un-Audited Standalone And Consolidated Financial Results For Quarter Ended September 30, 2022.

 BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Monday, November 14, 2022, inter alia, to approve and take on record the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2022, amongst other routine matters. The trading window fhas been closed from October 1, 2022 to November 16, 2022 (both days inclusive). The Company will organize an Earnings Conference Call for analysts/investors on Tuesday, November 15, 2022.
20-10-2022
Bigul

BIOCON LTD. - 532523 - Statement Of Investor Complaints For The Quarter Ended September 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 037370 Name of the Signatory :- Mayank VermaDesignation :- Company Secretary and Compliance Officer
17-10-2022
Bigul

BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2022.
17-10-2022

Biocon in pact with Japan's Yoshindo to commercialise two biosimilar assets

 Yoshindo will get exclusive commercialisation rights in Japan for bUstekinumab and bDenosumab, developed and manufactured by Biocon Biologics, for an addressable market opportunity of over $700 million.
17-10-2022
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press release titled 'Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan'.
17-10-2022

Biocon falls 12% in 5 days on one major 'deficiency' alert for API unit

 The pharma company said it will respond to the European medical regulator with appropriate corrective and preventive actions within the stipulated time.
12-10-2022
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release titled 'Biocon Foundation Receives 'Mahatma Award 2022 for Excellence in Social Good'
07-10-2022
Bigul

BIOCON LTD. - 532523 - Notification To Stock Exchanges

 'This is to inform you that the European Directorate for the Quality of Medicines & HealthCare (EDQM) conducted a GMP inspection of an API manufacturing site of Biocon Limited in Bangalore from the 12th to 14th of September 2022 and issued a list of deficiencies on 5th October 2022. There were no critical deficiencies and one deficiency cited under the category 'Major'. We will be responding to the agency with appropriate corrective and preventive actions within the stipulated time. Biocon remains committed to the Quality, Safety & Efficacy of its products.' The above information will also be available on the website of the Company at www.biocon.com.
06-10-2022
Next Page
Close

Let's Open Free Demat Account